Microsoft launches the Biotech Scaler Program to accelerate the development of biotech and medtech startups, in partnership with Institut Curie

Issy-les-Moulineaux, June 16, 2022 – Microsoft France today announces the launch of the Biotech Scaler Program alongside its partners: Institut Curie and Cellenza. The initiative, intended for biotech and medtech, aims to accelerate their development by providing them with technological and analytical tools, and to support them in their investment research. 4 startups are already part of the program: MabSilico, WhiteLab Genomics, Ose Immunotherapeutics and Caranx.

The Biotech Scaler Program brings together startups that develop Artificial Intelligence platforms to identify new targets or drug candidates and biotech startups that develop new platforms in immunotherapy, gene or cell therapy, to treat cancers, rare diseases or orphans. These companies, which are today at the forefront of innovation, nevertheless face long development cycles and require significant capital injections. To help them make rapid progress in their research and pursue their development, Microsoft France wanted to create a dedicated support program for them.

Institut Curie, a partner of the Biotech Scaler Program, will also guide startups from its incubator towards this program. “Moving from promise to product is the main challenge for biotechs. By integrating the Biotech Scaler Program into our incubator, we give an additional advantage to the companies resulting from our research to accelerate their development and provide patients with innovative treatments. The early choice of a good digital architecture is essential to be credible in discussions with investors, manufacturers or regulatory authorities and to differentiate yourself from the competition which is global. » says Dr. Amaury Martin, Deputy Director in charge of Technology Transfer, Industrial Partnerships and Data at Institut Curie.

The Biotech Scaler Program thus offers participants:

  • Technological support: through the Founders Hub, Microsoft’s program for startups, Microsoft will offer startups in the Biotech Scaler Program free Azure credits, access to advice from our devops teams on their digital architecture and support for the development of their sheet road when they enter the scale up phase, organized by Cellenza
  • A mentoring program in the search for investments: DNA Finance Investment & Advisory will guide the startups in the program in their fundraising.

The Biotech Scaler Program is a tacit agreement that does not include any financial commitment or contractualization.

“The Biotech Scaler Program is a new kind of support program, specifically designed to meet the needs of biotech startups whose development may require extremely rapid scaling. We provide them with a set of digital tools and skills to enable them to meet these needs. » says Charles Calestroupat, Director of the Public Sector Entity of Microsoft France.

Press Contact: Hopscotch Agency for Microsoft

Amélie Rochette – 01 41 34 20 27– [email protected]

Leave a Comment